Drugs / MTX
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04511702 Background | Oct 2020 → Jan 2024 | gout | Amgen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04511702 ↗ |
| Route | Oral | “weekly oral methotrexate” NCT04511702 ↗ |